Government of Canada invests in research commercialization
$29 million investment in two commercialization centres will accelerate Canadians’ access to innovative cancer immunotherapies and natural products.
In Montréal, the Centre for Commercialization of Cancer Immunotherapy (C3i) will receive funding of $15 million over five years to develop, translate and commercialize cancer immunotherapy.
C3i, which is based in Montréal, will accelerate access to innovative cancer immunotherapies for patients. Operating out of the Hôpital Maisonneuve-Rosemont’s Research Centre, C3i will be a one-stop shop for the development, translation and commercialization of ground-breaking cancer treatments.